Down regulation of cyclin-dependent kinase inhibitor 1B (CDKN1B or also known as p27) is reported in approximately 60% of human cancer and also found to be associated with poor prognosis and resistance to chemotherapeutic drugs. This evidence concerns the gene CDKN1B and cancer.